Ignite Creation Date:
2024-10-26 @ 3:39 PM
Last Modification Date:
2024-10-26 @ 3:39 PM
Study NCT ID:
NCT06583070
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-08-24
Brief Title:
SABR Combined With Targeted Therapy and Anti-PD-1 for Recurrent or Metastatic Renal Cancer
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Cohort Study of SABR Combined With Targeted Therapy and Anti-PD-1 Versus Targeted Therapy and Anti-PD-1 for Recurrent or Metastatic Renal Cell Carcinoma Patients
Status:
RECRUITING
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
COSTAR
Brief Summary:
Renal cancer ranks seventh in incidence among men and sixth among women in the Beijing area with Peking University First Hospital treating over 1000 kidney cancer patients annually Once recurrence or metastasis occurs the prognosis is poor with median progression times of 1-2 years after first-line systemic therapy targeted therapy combined with immunotherapy Enhancing local control of lesions is key to improving overall survival Combining local radiotherapy with systemic treatment may be one approach to address this issue Currently Stereotactic Ablative Radiotherapy SABR enables precise tumor ablation and can activate the bodys immune response Studies show that the one-year local control rate after SABR exceeds 90 Preliminary research by the applicant has shown that the combination of drug therapy and SABR for recurrent metastatic renal cancer can extend progression-free survival beyond two years with earlier intervention leading to more significant survival improvements This study aims to evaluate the efficacy and safety of combining SABR with targeted and immunotherapy for recurrent metastatic renal cancer through a multicenter bidirectional cohort design exploring new therapeutic strategies
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None